The chemistry and interactions of the complement (C) attack proteins (C5-C9) are reasonably well defined, but the control of this powerful biological effector system is not as well understood. It is the aim of this research to approach the study of control of the C attack system from two different aspects. First, studies on the inhibition of the action of the C5b67 complex by serum proteins will be continued. The roles of C8 and its subunits, lipoproteins and their apoprotein constituents, and other potential serum inhibitors (S protein) will be quantified and defined by preparing serum reagents free of these activities. Results will be confirmed using purified, radiolabeled C components. To demonstrate the potential in vivo relevance of these control mechanisms, additional studies will be performed in whole serum systems in which zymosan or immune complexes are used to activate the C attack mechanism. The relative effectiveness of C5b67 attachment to guinea pig erythrocytes in sera depleted of various C567 inhibitors will be evaluated by functional (lytic) and radioisotope tracer methods. The second approach will investigate the mechanism by which tumor cells resist C attack. Using labeled C5b6, the fate of C5b67 complexes bound to lymphoblastoid cells will be followed. Clearance of complexes from cells will be correlated with the ability of the C attack proteins to kill the cells. The effects of membrane-bound C3 fragments on the susceptibility of tumor cells to C-mediated cytotoxicity will be quantitatively assessed and correlated with the specific binding of labeled C components to the target cell. This study represents one of the first investigations into the interaction between the isolated human C attack proteins and human nucleated cells and as such may produce fundamental new information on the role of the complement attack mechanism in the destruction of tumor cells. (HF)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA026143-07
Application #
3167200
Study Section
Experimental Immunology Study Section (EI)
Project Start
1979-07-01
Project End
1987-12-31
Budget Start
1986-01-01
Budget End
1986-12-31
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Rush University
Department
Type
Overall Medical
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Zeller, J M; Caliendo, J; Lint, T F et al. (1988) Changes in respiratory burst activity during human monocyte differentiation in suspension culture. Inflammation 12:585-95
Gawryl, M S; Chudwin, D S; Langlois, P F et al. (1988) The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31:188-95
Doglio, L T; Gawryl, M S; Lint, T F (1988) Analysis of human C8 with monoclonal antibodies. Characterization of a monoclonal antibody that recognizes free C8 alpha-gamma subunit. J Immunol 141:2079-83
Langlois, P F; Gawryl, M S (1987) Identical complement concentrations in blood obtained from central venous catheters, arterial lines, and antecubital phlebotomy. J Lab Clin Med 110:495-7
Bara, S; Lint, T F (1987) The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages. J Immunol 138:1303-9
Lint, T F; Gewurz, H (1986) Component deficiencies. 9. The ninth component. Prog Allergy 39:307-10
Gawryl, M S; Simon, M T; Eatman, J L et al. (1986) An enzyme-linked immunoabsorbent assay for the quantitation of the terminal complement complex from cell membranes or in activated human sera. J Immunol Methods 95:217-25
Zeller, J M; Landay, A L; Lint, T F et al. (1986) Aggregated C-reactive protein binds to human polymorphonuclear leukocytes and potentiates Fc receptor-mediated chemiluminescence. J Lab Clin Med 108:567-76
Zeller, J M; Landay, A L; Lint, T F et al. (1986) Enhancement of human peripheral blood monocyte respiratory burst activity by aggregated C-reactive protein. J Leukoc Biol 40:769-83